LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

被引:0
|
作者
Kupas, K. [1 ]
Kaspar, I. [1 ]
Baecke, V. [2 ]
Weisel, K. [3 ]
机构
[1] Bristol Myers Squibb, Munich, Germany
[2] Ecker Ecker GmbH, Hamburg, Germany
[3] Univ Tubingen, Tubingen, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
E1256
引用
收藏
页码:514 / 515
页数:2
相关论文
共 50 条
  • [1] Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
    Siegel, David S.
    Schiller, Gary J.
    Song, Kevin W.
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    Kaya, Hakan
    Sebag, Michael
    Samaras, Christy
    Malek, Ehsan
    Talamo, Giampaolo
    Seet, Christopher S.
    Mouro, Jorge
    Pierceall, William E.
    Zafar, Faiza
    Chung, Weiyuan
    Srinivasan, Shankar
    Agarwal, Amit
    Bahlis, Nizar J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 501 - 510
  • [2] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Leleu, Xavier
    Tsao, L. Claire
    Westland, Christopher
    Singhal, Anil K.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
  • [3] Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma
    Wang, Chunling
    He, Zhengmei
    Shi, Yuye
    Zhang, Lijuan
    Chen, Yue
    Chen, Zhi
    Yu, Liang
    HEMATOLOGY, 2017, 22 (02) : 88 - 92
  • [4] Phase III trial of thalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 452 - 453
  • [5] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Dao-bin Zhou
    Li Yu
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Dena DeMarco
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Jian Hou
    International Journal of Hematology, 2015, 101 : 569 - 577
  • [6] A STATISTICAL COMPARISON OF THE EFFICACY AND SAFETY OF LOW-DOSE LENALIDOMIDE plus LOW- DOSE DEXAMETHASONE WITH FULL-DOSE LENALIDOMIDE plus DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Quach, H.
    Fernyhough, L.
    Henderson, R.
    Corbett, G.
    Honemann, D.
    Blacklock, H.
    Browett, P.
    Link, E.
    Cowan, L.
    Li, J.
    Swern, A.
    Hussein, M.
    Lynch, K.
    Dimopoulos, M.
    Prince, M.
    HAEMATOLOGICA, 2012, 97 : 350 - 351
  • [7] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Zhou, Dao-bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    DeMarco, Dena
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 569 - 577
  • [8] Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
    Lee, Sung-Eun
    Lim, Ji-Young
    Ryu, Da-Bin
    Kim, Tae Woo
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Min, Woo-Sung
    Min, Chang-Ki
    BLOOD, 2015, 126 (23)
  • [9] Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald P.
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Agarwal, Amit
    Chung, Weiyuan
    Zafar, Faiza
    Bahlis, Nizar
    BLOOD, 2018, 132
  • [10] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Seok Jin Kim
    Danbee Kang
    Yong Park
    Yeung-Chul Mun
    Kihyun Kim
    Jin Seok Kim
    Chang-Ki Min
    Juhee Cho
    Supportive Care in Cancer, 2021, 29 : 4969 - 4977